Free Trial
ASX:MSB

Mesoblast (MSB) Stock Price, News & Analysis

Mesoblast logo

About Mesoblast Stock (ASX:MSB)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
10.19 million shs
Average Volume
N/A
Market Capitalization
$2.32 billion
P/E Ratio
N/A
Dividend Yield
2.58%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Receive MSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

MSB Stock News Headlines

My prediction is coming true
We've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by using a secret we tested against every horrible thing that's happened to our financial system since 1991.
See More Headlines

MSB Stock Analysis - Frequently Asked Questions

Mesoblast Limited (ASX:MSB) posted its earnings results on Thursday, February, 21st. The company reported ($0.09) EPS for the quarter. Mesoblast had a negative net margin of 1,490.27% and a negative trailing twelve-month return on equity of 17.79%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include Mesoblast (MESO), Fortescue (FMG), Strategy (MSTR), Aus Tin Mining (ANW), OceanaGold (OGC), Piedmont Lithium (PLL) and Alliance Resource Partners (ARLP).

Company Calendar

Last Earnings
2/21/2019
Today
4/20/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
Trading
Current Symbol
ASX:MSB
CIK
N/A
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
9.56
Net Income
$-87,960,000.00
Net Margins
-1,490.27%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.90 million
Price / Cash Flow
30.00
Book Value
A$0.43 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,140,000,000
Free Float
N/A
Market Cap
$2.32 billion
Optionable
Not Optionable
Beta
2.38

This page (ASX:MSB) was last updated on 4/20/2025 by MarketBeat.com Staff
From Our Partners